U.S. Markets closed

Roche Holding AG (RHHBY)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
34.43+0.14 (+0.39%)
At close: 3:59PM EDT
People also watch
Interactive chart
Previous Close34.29
Bid0.00 x
Ask0.00 x
Day's Range34.30 - 34.67
52 Week Range25.25 - 36.82
Avg. Volume1,109,429
Market Cap234.29B
PE Ratio (TTM)24.58
Earnings DateN/A
Dividend & Yield1.03 (3.00%)
Ex-Dividend Date2017-03-15
1y Target EstN/A
Trade prices are not sourced from all markets
  • Incyte Teams Up With Dow's Merck To Trounce Roche In Cancer
    Investor's Business Daily4 days ago

    Incyte Teams Up With Dow's Merck To Trounce Roche In Cancer

    Incyte stock popped to a month-high Thursday after its immuno-oncology drug proved effective in matchups with Merck's Keytruda and Bristol's Opdivo.

  • Reuters5 days ago

    Merck says test shows Keytruda improves survival for bladder cancer patients

    Pivotal trial results for Merck & Co Inc's immunotherapy drug Keytruda show that it lengthened survival by three months, or nearly 40 percent, for patients with advanced bladder cancer who had stopped responding to chemotherapy. The data, to be presented next month at a meeting of the American Society of Clinical Oncology, follow last week's announcement that rival drug Tecentriq, from Roche Holding AG , did not improve survival when used as a second-line treatment for bladder cancer in a trial. The Merck drug is awaiting U.S. Food and Drug Administration approval, but Tecentriq was approved by the agency last year, contingent on verification of its clinical benefit.

  • Bloomberg6 days ago

    Roche Seeks to Mend Damaged Nerves in Multiple Sclerosis Push

    Roche Holding AG is seeking a partner with experimental drugs that might help repair the damage caused to the nervous system by multiple sclerosis -- considered a key step in managing the debilitating ...